- Home
- CRNX vs GRFS Comparison
CRNX vs GRFS Comparison
Compare CRNX & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- GRFS
- Stock Information
- Founded
- CRNX 2008
- GRFS 1940
- Country
- CRNX United States
- GRFS Spain
- Employees
- CRNX N/A
- GRFS N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- CRNX Health Care
- GRFS Health Care
- Exchange
- CRNX Nasdaq
- GRFS Nasdaq
- Market Cap
- CRNX 5.3B
- GRFS 6.0B
- IPO Year
- CRNX 2018
- GRFS 2006
- Fundamental
- Price
- CRNX $54.72
- GRFS $9.45
- Analyst Decision
- CRNX Strong Buy
- GRFS Sell
- Analyst Count
- CRNX 10
- GRFS 2
- Target Price
- CRNX $73.70
- GRFS $10.50
- AVG Volume (30 Days)
- CRNX 655.3K
- GRFS 1.0M
- Earning Date
- CRNX 11-12-2024
- GRFS 01-01-0001
- Dividend Yield
- CRNX N/A
- GRFS N/A
- EPS Growth
- CRNX N/A
- GRFS N/A
- EPS
- CRNX N/A
- GRFS 0.27
- Revenue
- CRNX $1,038,999.00
- GRFS $7,814,096,584.00
- Revenue This Year
- CRNX N/A
- GRFS $8.86
- Revenue Next Year
- CRNX $494.25
- GRFS $7.00
- P/E Ratio
- CRNX N/A
- GRFS $41.33
- Revenue Growth
- CRNX N/A
- GRFS 7.21
- 52 Week Low
- CRNX $28.50
- GRFS $5.30
- 52 Week High
- CRNX $62.53
- GRFS $12.15
- Technical
- Relative Strength Index (RSI)
- CRNX 41.37
- GRFS 62.73
- Support Level
- CRNX $58.21
- GRFS $8.69
- Resistance Level
- CRNX $62.53
- GRFS $9.75
- Average True Range (ATR)
- CRNX 2.48
- GRFS 0.37
- MACD
- CRNX -0.33
- GRFS 0.06
- Stochastic Oscillator
- CRNX 4.87
- GRFS 80.27
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.